one4all
23 May 2016
Re: now the RNS to confirm it..1p now yessssss
one4all
23 May 2016
now the RNS to confirm it..BOOOOMMM buy
one4all
23 May 2016
TRIAL TO START 31st MAY get on it
one4all
12 May 2016
1.2p coming soon to a share near you BUY
one4all
12 May 2016
1.2p coming soon to a share near you BUY
one4all
12 May 2016
global recognition now...BUY BUY BUY [link]
one4all
12 May 2016
time to buy, news next week the NHS trials approval should be with us back end of next week. a milestone in the history of SAR.. now is the time to accumulate
fredd1eboy
10 Apr 2016
Copied from LSe FOR INFO AstraZeneca cancer drug approved on NHS, but with strings attachedThe first ovarian cancer treatment to get approval from the NHS in over a decade will be heavily subsidised by the pharmaceuticals giant EmailAstraZenecaAstraZeneca is calling for urgent reform to the way patients are given access to novel medications in the UK Photo: GETTYJulia Bradshaw12:53PM GMT 11 Dec 2015AstraZeneca has won a battle to give British patients access to one of its ground-breaking ovarian cancer drugs, but only after agreeing to part-fund the scheme.The National Institute for Health and Care Excellence, which decides which drugs should be available to NHS patients in England and Wales, said in draft final guidance that it would be prepared to recommend that olaparib, known by its brand name Lynparza, be given to women with some forms of ovarian cancer.The landmark decision is a U-turn for the UK drugs gatekeeper, which initially decided to reject the drug in June.If given the green light, olaparib would be the first medicine for ovarian cancer approved by NICE since 2003 and highlights the squeeze many pharmaceuticals companies are facing as the UK government continues to keep a tight lid on healthcare costs.While the UK is a leader in life sciences, the lack of willingness on the Government's part to spend money on new drug treatments developed by UK scientists has become a major frustration for pharmaceuticals firms, many of whom are seriously talking about pulling their research and development teams out of the UK, according to Telegraph sources.ADVERTISING The ovarian cancer drug will help 400 women a yearThe ovarian cancer drug will help 400 women a year Photo: NewscastOne industry source said the UK was known as "low and slow" and was restricting innovation because it can't afford to pay for the drugs on the health service."NICE has not changed its methodology in 16 years despite the landscape changing, because as soon as it does, it will open a Pandora’s box of medicines," the person said."There will be a tipping point in the next three to five years. NICE is not saying yes enough. Would you put your new R&D centre in a place that does not appreciate innovation needs?"The NICE decision on olaparib comes 12 months after the drug was approved by European regulators, a timeframe that some industry experts claim is too long given that the patients eligible to use the drug have an average life expectancy of just 24 months."We’ve seen a partial easing today in the bottleneck for innovative new cancer drugs reaching patients," said Professor Paul Workman, chief executive of the Institute of Cancer Research."Olaparib's approval by NICE is a defining moment in the history of targeted cancer treatments, although it is still frustrating that under the terms of the judgement patients cannot benefit until they have had at least three rounds of chemotherapy."All other public health bodies in Europe that have reviewed olaparib, which was discovered and developed in the UK, have given access to all patients, including France, Germany, Sweden, Denmark, Netherlands, Luxembourg and Croatia. It has been available to women in the US since the beginning of 2015.The drug will only be offered to women in England and Wales who have already completed three or more rounds of chemotherapy, estimated to number roughly 400 a year, and AstraZeneca has agreed to foot the bill for patients who remain on the drug for more than 15 months.The pharmaceuticals firm has also agreed to sell the drug to the NHS at a reduced price. Olaparib costs £3,950 per pack; each box contains 448 capsules and is equivalent to 28 days' treatment.While AstraZeneca welcomed the decision, it called for urgent reform to the UK's health system."The review process and final decision for olaparib symbolise the urgent need for overall medicines access reform," said Lisa Anson, president for AstraZeneca UK and Ireland.Despite bein
Ripley94
06 Apr 2016
Re: Another 200% up.... I know the feeling AIM i feel is set up to make brokers lots of money, lots of them set up purely to get involved in issues then further issues and ramp them on to PI.I often wonder how long they hang on to clients .Plenty of new ones to replace them attracted by greed.The city is full of crooks can this system last ?
Urals1
06 Apr 2016
Another 200% up.... ....and I would have broken even on this dog of a share.Sorry, with experience penny shares that have this volatility have no hope.
Ripley94
05 Apr 2016
Re: Certainly not worth selling sliced again today @ 0.98 .Then noticed a RNS around 10.30. It went 0.24 higher soon after @ 1.2 but dropped back to RNS level by 4 pm.
one4all
05 Apr 2016
I love it when research comes together watch for next two announcements. this is going stratospheric and global
si derman
05 Apr 2016
Re: looks better today Indeed. Only nipped in for coffee and saw the drop on the 1 day chart. Then news dropped. Managed to get back in around where I got out last week.Might not get much work done. lolGLS
Gazzleberry
05 Apr 2016
Re: looks better today And looks a lot better today. Very nice RNS.Gary
one4all
01 Apr 2016
looks better today BUY
